A Modern announced on Tuesday, 5, in a statement on its website, that the European Medicines Agency (EMA) authorized the administration of a third dose of the vaccine against covid-19 developed by the pharmaceutical company to immunodeficient people in the territory gives European Union (EU).
- Want to know all about covid-19 vaccine development and effectiveness? Sign the EXAM and stay inside.
According to the company, the third dose should be administered at least 28 days after the second dose of the vaccine, in order to reinforce protection in “severely immunocompromised individuals aged 12 years or more”.
According to the American drugmaker, a “growing number” of studies have shown the benefits of a third dose in people with immune systems that have a less robust response to vaccines.